CagriSema vs Zepbound: How They Compare

If you are weighing CagriSema against Zepbound, the most important fact is availability: Zepbound (tirzepatide) is FDA approved and you can start it now, while CagriSema is still investigational and not available at all. On effectiveness the two are close, but in the one trial that pitted them directly against each other, Zepbound came out ahead. CagriSema combines semaglutide with the amylin analog cagrilintide; Zepbound is a single dual-receptor drug. Here is how they compare on results, availability, mechanism, and side effects.

The headline: a head-to-head actually exists

Most emerging-drug comparisons rely on cross-trial guesswork, but here there is direct evidence. Novo Nordisk ran REDEFINE 4, an 84-week trial comparing CagriSema against tirzepatide 15 mg in adults with obesity. The results, reported in early 2026, showed CagriSema produced slightly less weight loss than tirzepatide and did not demonstrate the superiority Novo had hoped for. When measured directly, Zepbound’s molecule held the edge.

That matters because cross-trial numbers can mislead. CagriSema’s ~22.7% in REDEFINE 1 and tirzepatide’s ~21% in SURMOUNT-1 look nearly identical on paper, but a head-to-head is the cleaner test, and it favored tirzepatide.

Side by side

How the mechanisms differ

Both drugs use a GLP-1 signal to reduce appetite, but they add a different second mechanism. CagriSema adds amylin (via cagrilintide), a fullness hormone that works through the brainstem. Zepbound adds GIP, a second incretin hormone that appears to improve how the body handles fat and may ease nausea compared with GLP-1 alone.

Neither approach is clearly better in principle; what matters is the outcome data, and so far tirzepatide’s trial record is strong and, importantly, already proven in everyday use.

Availability is the practical difference

This is the part that decides most real choices. Zepbound can be prescribed today and has been used by hundreds of thousands of people, with documented before-and-after results and a known safety profile. CagriSema has not been used outside of clinical trials, cannot be prescribed or compounded, and is not expected to reach pharmacies until late 2026 or 2027 at the earliest, if the FDA approves it. (Zepbound and Mounjaro are the same drug for different uses, which sometimes causes confusion; here is a clear explanation.)

Side effects

Both are gastrointestinal-forward, which is typical for the class: nausea, constipation, diarrhea, and occasional vomiting, mostly during dose escalation and mostly mild to moderate. There is no clear tolerability winner in the available data, and individual response varies, which is one reason supervised dosing matters.

Which makes sense for you?

Consider a scenario where someone is deciding whether to start Zepbound now or hold out for CagriSema. Given that Zepbound is approved, available, and won the only direct comparison so far, waiting for CagriSema would mean delaying effective treatment for a drug that, on current evidence, does not clearly beat what you can already get.

CagriSema is worth watching, especially once real-world data emerges, but it is not a reason to postpone treatment. You can check whether Zepbound or another approved option fits you through a quick assessment, and revisit CagriSema if and when it launches.

This article is for educational purposes only and is not medical advice. CagriSema is investigational and not FDA approved or available by prescription; the comparisons here draw on separate clinical trials and one head-to-head study, not on real-world use of CagriSema. Treatment decisions depend on your individual health, so always consult a licensed healthcare provider before starting, stopping, or changing any medication.